TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Distal sensory latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: First event of ventricular tachycardia or fibrillation
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival at 9 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall incidence of any grade adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Echocardiographic parameters related to diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BNP-32 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: motoneuron pool excitability Hmax/Mmax ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint position sense inversion variable error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of ICU stay (LOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from onset of sepsis to beginning of anti-Candida treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SCORAD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in plasma HVA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in plasma cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: radiological damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration of aesthetic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS while coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peak urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urethral stricture development
Endpoint domain: Adverse events/effects
Primary endpoint: plasma choline concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of phlebographic venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PASAPQ performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in moderate to severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: remission criteria met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alertness and focused and sustained attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of perineal trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion readmitted within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Correct dosing adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional memory contextualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of chemoprevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-year actuarial larynx preservation rate
Endpoint domain: Mortality/survival
Primary endpoint: Duration of clinical response to Sinemet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Assessment of Chronic Illness Care score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client Perceptions of Coordination Questionnaire endorsement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preload Duration for the non-dominant hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miscarriage rate
Endpoint domain: Adverse events/effects
Primary endpoint: fentanyl-sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: oral reading performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FVIIa potencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: OC completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median RPE values
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma ADMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean total body lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thigh muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of flushing-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in alanine aminotransferase and aspartate aminotransferase levels
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in fasting blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early postoperative hypotony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: mean serum levels of ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: mean serum levels of AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: gastrointestinal disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Viable and apoptotic circulating endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Circulating mRNA coding for VEGFR‐C and D and PDGFR‐β
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving obliteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of diarrhoea in days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abstinence from smoking at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBLT performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMJ force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15 m SPRINT times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: guideline adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total, moderate and no anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Satisfaction with communication about aging-related concerns (patients)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with communication about aging-related concerns (caregivers)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of aging-related conversations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower dual-task costs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Constant Murley Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of people investigated for osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CADP‐CT prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in nasal and ocular symptoms of SAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival (EFS) at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Serious toxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in urinary peptidome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P300 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual analogue scale increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine-induced wheal and flare suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean score of correct answers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMSI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPECT score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone gain after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty of use (VAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insertion failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion time during chest compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintained response at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with exactly one follicle >= 16 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time for satisfactory anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for supplementary injections
Endpoint domain: Adverse events/effects
Primary endpoint: mean onset of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue analgesic requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Change in VEGFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day intention-to-treat abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrival time in the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrival time in the jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial-venous transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: visual dryness and erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: level of hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cerebral perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased number of headache-free days with normal functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: OBPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic variability (SD of glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment satisfaction improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: breast cancer screening disparity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Treatment persistence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to prescribed doses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of missed doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PF4 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal complement complex (TCC) generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal epithelial barrier improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCT Sluggish/Sleepy factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reporting of important clinical details
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BPRS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 2 to 3 esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of children reacting at the first dose
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Total VMS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean frequency of moderate/severe VMSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSA likelihood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal cuff healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval from hysterectomy to start of IVBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean absolute differences in alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed colonic transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CD4 cell count changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pVL changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean duration of ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for homologous blood products
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: active joint position sense in 15° of inversion after muscle fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work in the last third of inversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulated doses of fentanyl and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of vasopressor drugs requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients developing tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Number of analgesic injections (nalbuphine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moDCs maturation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pru p 3-specific proliferation of effector cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: regulatory T (Treg) cells increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LTM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance (FP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil phagocytic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-infinity) of intravenous oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-infinity) of orally administrated oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (GIR 0 - 6 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (IAsp 0 - 6 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall IAsp exposure (AUC 0 - 12 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain during infiltration anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enhancement of clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bucco-lingual tipping of the molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term phonological memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: recall strategies development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall distress reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grief level reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in morning pre-dose (trough) FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in trough FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with ≥1 treatment-emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Avoidance of nephrostomy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CGIS‐P scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of predischarge vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hypokalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hypomagnesemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FEV1.0 (Forced Expiratory Volume in 1 second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TGF-beta1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Verbal rating scores (VRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained cure/presumed eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median changes in BHB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interexaminer reliability for horizontal SCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interexaminer reliability for vertical SCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeat surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Collagen fiber network integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accomplishment of preoperative autologous blood collection program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in objective bulimic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in purging behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal mortality ratio
Endpoint domain: Mortality/survival
Primary endpoint: Cost per screened person
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blastocyst rate per injected oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Removal of porphobilinogen from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of recombinant human porphobilinogen deaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of antibodies against recombinant human porphobilinogen deaminase
Endpoint domain: Adverse events/effects